Doer Biologics published paper of a long-acting GLP-1R / GCGR dual-agonist for the treatment of diabetes and obesity
Recently, Doer Biologics published a research paper of a long-acting GLP-1R/GCGR dual-agonist fusion protein for the treatment of diabetes and obesity developed based on recombinant expression technology，it’s worth noting that this is the first case in the world. The results were published online in the Journal of Endocrinological Investigation on November 21, 2019, with Dr. Yanshan Huang as the corresponding author.
Type 2 diabetes (T2D) is the most common metabolic disease. GLP-1R agonists are mainly used to treat type 2 diabetes among the protein drugs currently on the market. GLP-1R agonist has obvious hypoglycemic effect. Compared with insulin, GLP-1R agonist has the advantage that its hypoglycemic effect is strictly dependent on blood glucose concentration, thus is not easy to cause hypoglycemia, and it has the effect of reducing body weight. According to the research results in recent years, the combination of multiple incretin receptor agonists has synergistic physiological effects, which can better control blood glucose and weight. Based on this mechanism, major domestic and foreign institutions have developed multi-effect agonists including GLP-1R/GCGR dual-agonists, GLP-1R/GIPR dual-agonist, and even GLP-1R/GCGR/GIPR triagonists, all of which are in preclinical or clinical research stages. In order to achieve long-acting effects in vivo, these drugs are mostly modified by fatty acid chain, PEG or by Fc conjugation. Doer Biologics obtained DR10601 which was developed by the fusion of dual-active polypeptide with GLP-1R/GCGR agonistic activity with human-derived Fc based on the technology of Multibody® platform. It’s a innovative drug candidate for obesity and Type II diabetes.
In the research paper released, the structure, physical and chemical properties in vitro and the efficacy in vivo of DR10601 were presented in detail. Datas show that DR10601 has superior properties and is a potential new generation of drug for obesity and Type II diabetes.
1.Wang, W. et al. (2019) ‘DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus’, Journal of Endocrinological Investigation. Springer International Publishing, (0123456789). doi: 10.1007/s40618-019-01153-z.
2.Stumvoll, M. and Tschöp, M. (2018) ‘Twice the benefits with twincretins?’, The Lancet, 392(10160), pp. 2142–2144. doi: 10.1016/S0140-6736(18)32466-8.
3.Brandt, S. J. et al. (2018) ‘Gut hormone polyagonists for the treatment of type 2 diabetes’, Peptides. Elsevier, 100(December 2017), pp. 190–201. doi: 10.1016/j.peptides.2017.12.021.